Consequently, specific money managers have jumped into Lion Biotechnologies Inc (NASDAQ:LBIO) headfirst. Sabby Capital, managed by Hal Mintz, created the biggest call position in Lion Biotechnologies Inc (NASDAQ:LBIO). Sabby Capital had $0.4 million invested in the company at the end of the quarter. Jim Simons’ Renaissance Technologies also initiated a $0.2 million position during the quarter. The following funds were also among the new LBIO investors: Matthew Tewksbury’s Stevens Capital Management, Ken Griffin’s Citadel Investment Group, and Mike Vranos’ Ellington.
Let’s go over hedge fund activity in other stocks – not necessarily in the same industry as Lion Biotechnologies Inc (NASDAQ:LBIO) but similarly valued. We will take a look at REX American Resources Corp (NYSE:REX), Dorian LPG Ltd (NYSE:LPG), Exar Corporation (NASDAQ:EXAR), and Vicor Corp (NASDAQ:VICR). This group of stocks’ market values are closest to LBIO’s market value.
|Ticker||No of HFs with positions||Total Value of HF Positions (x1000)||Change in HF Position|
As you can see these stocks had an average of 9 hedge funds with bullish positions and the average amount invested in these stocks was $54 million. That figure was $163 million in LBIO’s case. Exar Corporation (NASDAQ:EXAR) is the most popular stock in this table. On the other hand Vicor Corp (NASDAQ:VICR) is the least popular one with only 6 bullish hedge fund positions. Compared to these stocks Lion Biotechnologies Inc (NASDAQ:LBIO) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers and have more money invested in it, it may be a good idea to analyze it in detail and potentially include it in your portfolio.